Latest News and Press Releases

Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation Nurix anticipates nominating a clinical candidate within...

SAN FRANCISCO, April 03, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...

Two-year extension of ongoing research collaboration intended to generate multiple additional clinical candidates Nurix will receive a $15.0 million extension fee, and will remain eligible for up...

Researchers will apply the latest TPD drug discovery technology to target fusion proteins that cause pediatric cancer Cancer Grand Challenges is an initiative funded by Cancer Research UK SAN...

Disclosure of the discovery and structure of NX-1607, the first inhibitor of CBL-B to advance into clinical studies.

Nurix's Phase 1a/1b study of NX-2127 in adults with r/r B-cell malignancies to enroll new patients after partial clinical hold lifted

Nurix Therapeutics to participate in March investor conferences

Nurix to present at AACR2024 Annual Meeting

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update

Data reveal oncogenic scaffold function of BTK mutations that lack kinase activity and show these mutations remain susceptible to degradation by NX-2127 NX-2127 degrades BTK in patients regardless of...